Wednesday, November 25, 2009, 2:50am SGT - The Singapore stock market opens in 6 hours and 10 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Santarus Inc. (SNTS)

At 2:27AM SGT: 4.06 USD  Up 0.07 (1.75%)  
 MORE ON SNTS 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Santarus, Inc. (NGM:SNTS) Delayed quote dataEdit
Last Trade:4.06 USD
Trade Time:2:27AM SGT
Change:Up 0.07 (1.75%)
Prev Close:3.99
Open:3.99
Bid:4.06 x 500
Ask:4.07 x 600
1y Target Est:4.83
Day's Range:3.90 - 4.10
52wk Range:1.05 - 4.23
Volume:99,403
Avg Vol (3m):251,602
Market Cap:235.78M
P/E (ttm):N/A
EPS (ttm):-0.05
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add SNTS to Portfolio   Download Data

 HEADLINES 
•Santarus to Present at Piper Jaffray 21st Annual Health Care Conference
Business Wire (Tue 5:00pm)
•Santarus' Zegrid Facing Back-to-Back FDA Approval Dates
at Seeking Alpha (Fri, Nov 20)
•Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza
at Seeking Alpha (Mon, Nov 16)
•[$$] Biotech Stock Mailbag: Cardium Therapeutics
at RealMoney by TheStreet.com (Fri, Nov 13)
•SANTARUS INC Financials
EDGAR Online Financials (Tue, Nov 10)
•SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Nov 10)
•Santarus to Present at Lazard Capital Markets 6th Annual Healthcare Conference
Business Wire (Tue, Nov 10)
•Santarus Reports Strong Quarter
Zacks.com (Sun, Nov 8)
•New Star Analyst Rankings for Santarus, Inc.
StarMine (Thu, Nov 5)
•Santarus Inc. Q3 2009 Earnings Call Transcript
at Seeking Alpha (Thu, Nov 5)
•Santarus, Inc. Earnings Call scheduled for 5:00 pm ET today
CCBN (Thu, Nov 5)
•SANTARUS INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Thu, Nov 5)
•Santarus Reports Third Quarter 2009 Financial Results
Business Wire (Thu, Nov 5)
More Headlines for SNTS...
 ANALYST 
EPS Est (next year) (Dec-09) :0.29
EPS Est (in 2 years) (Dec-10) :0.25
Avg Rec (current)*:2.5
PEG Ratio:1.22
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices